Blue Trust’s Galectin Therapeutics GALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$27.2K Hold
7,000
– – ﹤0.01% 1410
2026
Q2
$32.5K Hold
7,000
– – ﹤0.01% 1514
2026
Q1
$19.5K Hold
7,000
– – ﹤0.01% 1653
2025
Q4
$29.1K Hold
7,000
– – ﹤0.01% 1553
2025
Q3
$29.6K Sell
7,000
-1,800
-20% -$6.77K ﹤0.01% 1563
2025
Q2
$18.6K Buy
8,800
+1,800
+26% +$2.69K ﹤0.01% 1699
2025
Q1
$8.54K Hold
7,000
– – ﹤0.01% 1961
2024
Q4
$9.03K Hold
7,000
– – ﹤0.01% 1974
2024
Q3
$15.8K Hold
7,000
– – ﹤0.01% 2037
2024
Q2
$16.7K Hold
7,000
– – ﹤0.01% 1738
2024
Q1
$16.7K Hold
7,000
– – ﹤0.01% 1297
2023
Q4
$13K Hold
7,000
– – ﹤0.01% 1482
2023
Q3
$10K Hold
7,000
– – ﹤0.01% 1405
2023
Q2
$15K Hold
7,000
– – ﹤0.01% 1157
2023
Q1
$8K Hold
7,000
– – ﹤0.01% 1658
2022
Q4
$11K Hold
7,000
– – ﹤0.01% 1505
2022
Q3
$9K Hold
7,000
– – ﹤0.01% 1372
2022
Q2
$11K Buy
+7,000
New +$10.1K ﹤0.01% 1168

Other funds holding GALT

Blue Trust's GALT Position: Q3 2026 in Review

Blue Trust held its Galectin Therapeutics (GALT) position steady in Q3 2026 at 7,000 shares worth $27.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1410.

Blue Trust first reported a position in GALT in Q2 2022 and has held it in 18 quarters since. The position peaked at $32.5K in Q2 2026. 88 funds tracked by Wall St. Rank hold GALT as of Q3 2026.

  • Blue Trust held 7,000 shares of Galectin Therapeutics worth $27.2K as of Q3 2026.
  • Blue Trust left its Galectin Therapeutics share count unchanged in Q3 2026.
  • Galectin Therapeutics made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #1410 holding.
  • Blue Trust first reported a position in Galectin Therapeutics in Q2 2022 and has held it in 18 quarters since.
  • Blue Trust's Galectin Therapeutics position peaked at $32.5K in Q2 2026.
  • 88 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.